









Becton, Dickinson (BD), founded in 1897, is a 
global medical technology company that 
manufactures and sells medical supplies, devices, 
laboratory equipment, and diagnostic products. 
Based in New Jersey, BD operates in over 50 
countries worldwide, employs 30,000 people, with 
$8.1 billion in annual revenue (2013).  
 
In the early-to-mid-1980s, journal articles, CDC data, and advocacy by academics and healthcare 
worker unions raised the issue of needle-stick injuries and their potential to transmit the HIV virus 
and other infections to healthcare workers. Several visible cases of injury, combined with effective 
activism, gained the attention of the health field. BD recognized this health and safety problem as a 
social need and a business opportunity, and in 1988, it introduced the first safety syringe, 
incorporating a sliding safety shield to protect the needle after use, reducing the risk of injury and 
infection. To pursue this opportunity:  
 BD needed to understand the range of usage circumstances that presented sharp object injury risks to 
health workers and understand how product innovations could address the issue 
 Given the initial lack of prioritization of this issue by healthcare organizations, BD would have to 
develop a strategy to engage healthcare facilities, frontline workers, and their stakeholders 
Realizing that product development alone would not be enough, BD built a shared value strategy:  
 Reconceiving products and markets: BD developed the industry’s broadest array of safety-
engineered devices, including “needleless” systems that eliminated the need to use traditional needles 
in the highest-frequency category for sharps injuries 
 Improving the local operating environment: BD forged local partnerships and health clusters to 
help raise awareness of the issues, influenced national policies on healthcare worker safety, trained 
hospital workers, and provided unrestricted grants for tracking and analysis of needle-stick injuries. 
This served to accelerate the health system’s adoption of safety devices 
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SHARED VALUE IN ACTION 
 
 
BD’s safety strategy, first in the U.S., and then globally, has led to 
substantial business growth and reduction in sharps injuries.  
Business results:  
 BD’s safety devices grew from approximately $5 million in 
revenue (1988) to approximately $250 million in revenue (1999) 
to $2.1 billion in revenue (2013) 
 Sales of safety devices in emerging markets have accelerated, 
with 2012 growth of 25%, and over 42% growth in China alone 
 Safety devices have been BD’s single largest source of growth 
over the past 25 years, and BD leaders anticipate that safety-
engineered devices will continue to be a source of positive sales growth for the company over the next 
five to ten years    
 BD has gained competitive advantage and enhanced its margin in a traditionally lower-margin, high-
volume business 
Social results:  
 Data from the International Healthcare Worker Safety Center indicated that sharps injuries to nurses 
declined by 51% between 1993 and 2004 
 By the late 2000s, BD supported policy changes in many countries, including the United States, the 
European Union, Russia, Brazil, and Taiwan; key legislation required the use of safety devices in health 
facilities 
BD’s remarkable growth in safety products has illuminated key lessons: 
 BD was able to design products and provide comprehensive education to local providers by partnering 
with leading scholars, researchers, and healthcare worker safety advocates 
 BD continues to innovate, developing new safety products and incubating opportunities in developing 
countries through its Global Health function; products such as the Emerald Syringe, which has reuse 
prevention and safety features, will reach more health workers globally while also reducing cost and 
waste 
BD believes that there are still substantial opportunities to improve safety:  
 In the U.S., non-hospital sites have not fully transitioned to safety technology  
 Internationally, most countries have lower rates of transition to safety devices versus the U.S. 
 Based on the high infectious disease prevalence among patients in many developing countries, there is 




RESULTS – VALUE FOR BUSINESS AND SOCIETY 
  
LESSONS LEARNED, CHALLENGES AND OUTLOOK 
 
BD's safety devices grew from 
$5 million in revenue in 1988, 
to approximately $250 million 
in revenue in 1999, to              
$2.1 billion in revenue   
in 2013 
